The efficacy of curcuminoids in improvement of ulcerative colitis symptoms and patients’ self‐reported well‐being: A randomized double‐blind controlled trial

Masoodi, Mohsen; Mahdiabadi, Mohammad Ali; Mokhtare, Marjan; Agah, Shahram; Kashani, Amir; Rezadoost, Amir Mansoor; Sabzikarian, Mohammad; Talebi, Atefeh; Sahebkar, Amirhossein

doi:10.1002/jcb.27273

Cited by 57 publications

(79 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lang et al () showed that 1‐month supplementation with 3 g/day curcumin was effective in inducing the clinical and endoscopic remission in patients with mild‐to‐moderate active UC. A randomized controlled trial by Masoodi et al () reported that the mean SCCAI score was significantly lower in patients who took 240 mg of curcuminoids nanomicelles in addition to mesalamine compared with the control group. On the contrary, Kedia et al () showed that supplementation with curcumin could not improve the clinical outcomes, such as clinical remission, clinical response, and mucosal healing in UC patients.…”

Section: Discussionmentioning

confidence: 99%

The effect of curcumin supplementation on clinical outcomes and inflammatory markers in patients with ulcerative colitis

Sadeghi

Mansoori

Shayesteh

et al. 2019

Phytotherapy Research

View full text Add to dashboard Cite

Background and aims Curcumin has anti‐inflammatory properties. The aim of this study was to evaluate the effect of curcumin on improvement of the disease activity in ulcerative colitis (UC). Methods In this randomized double‐blind clinical trial, 70 patients with mild‐to‐moderate UC were randomly assigned to curcumin (1,500 mg/day) or placebo intake for 8 weeks. Disease clinical activity, quality of life, serum levels of tumor necrosis factor alpha (TNF‐α), high‐sensitivity C‐reactive protein (hs‐CRP), erythrocyte sedimentation rate (ESR) values, and complete blood count were measured. Results Changes in Simple Clinical Colitis Activity Index score were significantly higher in the curcumin than the placebo group (–5.9 ± 2.08 vs. –2.1 ± 2.6; p = .001). The scores of Inflammatory Bowel Disease Questionnaire‐9 and quality of life were significantly higher in the intervention group compared to the control group (p = .006). Furthermore, the curcumin supplementation reduced the serum hs‐CRP concentration (–6.3 ± 13.6 vs. 3.7 ± 11.6 μg/ml; p = .01) and ESR levels significantly (–1.6 ± 2.7 vs. –0.09 ± 2.4 mm/hr; p = .02) in comparison with the control group. No significant changes were observed in the TNF‐α levels of both groups. Conclusions Consumption of the curcumin supplement, along with drug therapy, is associated with significant improvement of the clinical outcomes, quality of life, hs‐CRP, and ESR in patients with mild‐to‐moderate UC.

show abstract

Section: Discussionmentioning

confidence: 99%

The effect of curcumin supplementation on clinical outcomes and inflammatory markers in patients with ulcerative colitis

Sadeghi

Mansoori

Shayesteh

et al. 2019

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…Curcumin and the whole turmeric rhizome have some beneficial effects in the treatment of chronic diseases such as gastrointestinal, cardiovascular, and neurological disorders, diabetes, and several types of cancer [31][32][33][34][35]. Clinical trials based on curcumin administration have been published or are currently in progress, pointing out the expanding interest of the scientific community on the therapeutic potential of curcumin [36][37][38][39].…”

Section: Curcumin: Metabolism and Bioavailabilitymentioning

confidence: 99%

Interaction between Gut Microbiota and Curcumin: A New Key of Understanding for the Health Effects of Curcumin

2020

View full text Add to dashboard Cite

Curcumin, a lipophilic polyphenol contained in the rhizome of Curcuma longa (turmeric), has been used for centuries in traditional Asian medicine, and nowadays it is widely used in food as dietary spice worldwide. It has received considerable attention for its pharmacological activities, which appear to act primarily through anti-inflammatory and antioxidant mechanisms. For this reason, it has been proposed as a tool for the management of many diseases, among which are gastrointestinal and neurological diseases, diabetes, and several types of cancer. However, the pharmacology of curcumin remains to be elucidated; indeed, a discrepancy exists between the well-documented in vitro and in vivo activities of curcumin and its poor bioavailability and chemical instability that should limit any therapeutic effect. Recently, it has been hypothesized that curcumin could exert direct regulative effects primarily in the gastrointestinal tract, where high concentrations of this polyphenol have been detected after oral administration. Consequently, it might be hypothesized that curcumin directly exerts its regulatory effects on the gut microbiota, thus explaining the paradox between its low systemic bioavailability and its wide pharmacological activities. It is well known that the microbiota has several important roles in human physiology, and its composition can be influenced by a multitude of environmental and lifestyle factors. Accordingly, any perturbations in gut microbiome profile or dysbiosis can have a key role in human disease progression. Interestingly, curcumin and its metabolites have been shown to influence the microbiota. It is worth noting that from the interaction between curcumin and microbiota two different phenomena arise: the regulation of intestinal microflora by curcumin and the biotransformation of curcumin by gut microbiota, both of them potentially crucial for curcumin activity. This review summarizes the most recent studies on this topic, highlighting the strong connection between curcumin and gut microbiota, with the final aim of adding new insight into the potential mechanisms by which curcumin exerts its effects.

show abstract

“…The clinical improvement, which was defined as a reduction of UCDAI ≥ 3 or SCCAI ≥ 3, has no significant difference between curcumin and placebo. But Masoodi et al ., the trial included for systematic review, showed that the mean SCCAI score was significantly lower in the patients who received curcumin compared with placebo after 4 weeks of treatment (1.71 ± 1.84 vs 2.68 ± 2.09, P = 0.05).…”

Section: Discussionmentioning

confidence: 99%

“…Curcumin, a polyphenol derived from the turmeric plant ( Curcuma longa ), has been demonstrated to hold many health‐related benefits and pharmacological effects, including anti‐inflammatory, antibacterial actions, and improving symptoms of auto‐immune diseases . Adjuvant use of curcumin in UC has become quite common recently . Multiple animal and human studies suggested that the anti‐inflammatory effect of curcumin in UC was primarily mediated by inhibiting the inflammatory pathways and mediators, such as NF‐κB and TNF‐α .…”

Section: Introductionmentioning

confidence: 99%

Efficacy of adjuvant curcumin therapy in ulcerative colitis: A meta‐analysis of randomized controlled trials

Zheng

Wang

Chen

et al. 2019

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and Aim: Aminosalicylic acids are recognized to be the first-line treatment options for ulcerative colitis. Currently, the effectiveness of curcumin as an adjuvant treatment in ulcerative colitis has been investigated, which was still controversial. This study aimed to systematically review and meta-analyze the efficacy and safety of curcumin as an adjuvant treatment in ulcerative colitis. Methods: The PubMed, EMBASE, and Cochrane Library databases were searched from original to July 2019, and relevant randomized controlled clinical trials were enrolled and analyzed. The primary outcomes were clinical and endoscopic remission; meanwhile, the secondary outcomes were clinical and endoscopic improvement. Subgroup analyses of doses, delivery way, form, and intervention time of curcumin were also conducted. Results: Six randomized controlled clinical trials with a total of 349 patients were included. Eligible trials suggested that adjuvant curcumin treatment in ulcerative colitis was effective in inducing clinical remission (odds ratio [OR] = 5.18, 95% confidence interval [CI]: 1.84-14.56, P = 0.002), endoscopic remission (OR = 5.69, 95% CI: 1.28-25.27, P = 0.02), and endoscopic improvement (OR = 17.05, 95% CI: 1.30-233.00, P = 0.03), but not in clinical improvement (OR = 4.79, 95% CI: 1.02-22.43, P = 0.05). We can see the potential advantages in large dosage, topical enema, special drug form, and longer duration from the enrolled studies. There were no severe side effects reported. Conclusions: Curcumin, as an adjuvant treatment of mesalamine, was proved to be effective and safe in ulcerative colitis. Better efficacy can be achieved with suitable dose, delivery way, formation, and intervention time, which needs further study to verify. Figure 1 The results of the inverted funnel plot analysis of the (a) clinical remission, (b) endoscopic remission, (c) clinical improvement, and (d) endoscopic improvement. [Color figure can be viewed at wileyonlinelibrary.com] T Zheng et al. Effect of curcumin in ulcerative colitis

show abstract

The efficacy of curcuminoids in improvement of ulcerative colitis symptoms and patients’ self‐reported well‐being: A randomized double‐blind controlled trial

Cited by 57 publications

References 35 publications

The effect of curcumin supplementation on clinical outcomes and inflammatory markers in patients with ulcerative colitis

The effect of curcumin supplementation on clinical outcomes and inflammatory markers in patients with ulcerative colitis

Interaction between Gut Microbiota and Curcumin: A New Key of Understanding for the Health Effects of Curcumin

Efficacy of adjuvant curcumin therapy in ulcerative colitis: A meta‐analysis of randomized controlled trials

Contact Info

Product

Resources

About